Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cole Friedes

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Clinical Lung Cancer|April 19, 2023
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health SystemNikhil Yegya-Raman, Cole Friedes, Lova Sun, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2023
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung CancerNikhil Yegya-Raman, Abigail T Berman, Christine A Ciunci, et al.
Cancer|January 31, 2024
Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab eraMichelle Iocolano, Nikhil Yegya-Raman, Cole Friedes, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 16, 2023
Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidationNikhil Yegya-Raman, Sang Ho Lee, Cole Friedes, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Clinical Lung Cancer|April 19, 2023
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health SystemNikhil Yegya-Raman, Cole Friedes, Lova Sun, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2023
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung CancerNikhil Yegya-Raman, Abigail T Berman, Christine A Ciunci, et al.
Cancer|January 31, 2024
Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab eraMichelle Iocolano, Nikhil Yegya-Raman, Cole Friedes, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 16, 2023
Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidationNikhil Yegya-Raman, Sang Ho Lee, Cole Friedes, et al.
Pageof 4